Petaluma medical technology startup Oculus Innovative Sciences has licensed its product for a potential acne drug.

New Jersey-based AmDerma Pharmaceuticals exercised its option to license rights to Oculus' Microcyn technology for development of the skin medication, Oculus officials said last week.

Microcyn is an anti-infection liquid used in dermatology, wound care, oral care, cosmeceuticals and veterinary care.

Oculus sells Microcyn products in the U.S., Mexico, Europe, India, China and parts of the Middle East.

AmDerma also licensed the rights to help Oculus promote existing Microcyn-based wound care products in the U.S. podiatry market, and licensed U.S. and Canadian rights to a Microcyn-based dermatology atopic dermatitis hydrogel that received FDA clearance in February.